FML vaccine against canine visceral leishmaniasis: From second-generation to synthetic vaccine

Expert Review of Vaccines

Volumn 7, Issue 6, 2008, Pages 833-851

  Palatnik de Sousa, Clarisa B ^a   Barbosa, André De Figueiredo ^b   Oliveira, Sandra Maria ^b   Nico, Dirlei ^a   Bernardo, Robson Ronney ^c   Santos, Wania R ^b   Rodrigues, Mauricio M ^d   Soares, Irene ^e   Borja Cabrera, Gulnara P ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Canine visceral leishmaniasis; CP05 saponin; DNA vaccine; FML antigen; Human visceral leishmaniasis; Leishmania chagasi; Leishmania donovani; Nucleoside hydrolase; QS21 saponin; Second generation vaccine; Transmission blocking vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; BLOCKING ANTIBODY; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE A; CYSTEINE PROTEINASE B; DNA VACCINE; FUCOSE MANNOSE LIGAND ANTIGEN; FUCOSE MANNOSE LIGAND ANTIGEN SAPONIN R VACCINE; GLYCOPROTEIN; GLYCOPROTEIN GP 36; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LACK ANTIGEN; LEISHMANIA VACCINE; LEISHMUNE; LIPOPHOSPHOGLYCAN; PROTOZOON ANTIBODY; QS 21; QUIL A; RECOMBINANT GLYCOPROTEIN GP 63; RECOMBINANT PROTEIN; SAPONIN; SAPONIN CP 05; SAPONIN DERIVATIVE; SAPONIN R; TRANSMISSION BLOCKING VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY RESPONSE; BRAZIL; DELAYED HYPERSENSITIVITY; DIAGNOSTIC VALUE; DISEASE MARKER; DNA IMMUNIZATION; DOG DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; NONHUMAN; PRIORITY JOURNAL; REVIEW; VISCERAL LEISHMANIASIS;

EID: 49449094129     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.6.833     Document Type: Review

References (138)

1. Mauricio IL, Gaunt MW, Stothard JR et al. Genetic typing and phylogeny of the Leishmania donovani complex by restriction analysis of PCR amplified gp63 intergenic regions. Parasitology 122, 393-403 (2001).
2. Alvar J, Cañavate C, Gutiérrez-Solar B et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10, 298-319 (1997).
3. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies? Am. J. Trop. Med. Hyg. 52, 287-292 (1995).
4. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55, 125-130 (1996).
5. Khalil EAG, El Hassan AM, Zijlstra EE et al. Autoclaved Leishmania major vaccine for prevention of viscral leishmaniasis: a randomised, doubled-blind, BCG-controlled trial in Sudan. Lancet 356, 1565-1569 (2000).
6. Turco SJ. The lipophosphoglycan of Leishmania. Parasitol. Today 4, 55-257 (1988).
7. Etges R, Bouvier J, Bordier C. The major surface protein of Leishmania promastigotes is a protease. J. Biol. Chem. 261, 9098-9101 (1986).
8. Späth GF, Lye LF, Segawa H et al. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301, 1241-1243 (2003).
9. Bouvier J, Schneider P, Etges R et al. Peptide substrate specificity of the membrane-bound metalloprotease of Leishmania. Biochemistry 29, 10113-10119 (1990).
10. Russell DG, Wright SD. Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes. J. Exp. Med. 168, 279-292 (1988).
11. Russell DG, Talamas-Rohana P, Zelechowski J. Antibodies raised against synthetic peptides from the Arg-Gly-Aspcontaining region of the Leishmania surface protein gp63 cross-react with human C3 and interfere with gp63-mediated binding to macrophages. Infect. Immun. 57, 630-632 (1989).
12. Palatnik CB, Previato JO, Gorin PAJ, Mendonça-Previato L. Partial chemical characterization of the carbohydrate moieties in Leishmania adleri glycoconjugates. Mol. Biochem. Parasitol. 14, 41-54 (1985).
13. McConville MJ, Bacic A. A family of glycoinositol phospholipids from Leishmania major. Isolation, characterization and antigenicity. J. Biol. Chem. 264, 757-766 (1989).
14. Palatnik CB, Previato JO, Gorin PAJ et al. Leptomonas samueli glycoconjugates. Comparison with Herpetomonas samuelpessoai. Comp. Biochem. Physiol. 86, 593-599 (1987).
15. Mendonça-Previato L, Gorin PA, Previato JO. Investigations on polysaccharide components of cells of Herpetomonas samuelpessoai grown on various media. Biochemistry 18, 149-154 (1979).
16. Palatnik CB, Borojevic R, Previato JO et al. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect. Immun. 57, 754-763 (1989).
17. Wilson ME, Pearson RD. Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J. Immunol. 136, 4681-4688 (1986).
18. Olafson RW, Wallis AE, Mc Master R. Structure studies and surface glycoproteins of Leishmania promastigotes: isolation, aminoacid composition and aminoterminal sequence studies. In: Host-Parasite Cellular and Molecular Interactions in Protozoal Infections. In: NATO ASI Series (Volume H11). Chang KP, Sneary D (Eds). Springer, Berlin, Germany 149-156 (1987).
19. Palatnik CB. Os glicoconjugados ligantes do receptor de interiorizaçåo para promastigotas de Leishmania donovani (LD 1S Sudan) em macrófagos peritoneais murinos, såo espécie-específicos. PhD Tesis. Universidad Federal do Rio de Janeiro, RJ, Brazil 34-50 (1989).
20. Palatnik-de-Sousa CB, Dutra HS, Borojevic R. Leishmania donovani surface glycoproteins GP36, is the major immunogen component of the fucose mannose ligand (FML). Acta Trop. 53, 59-72 (1993).
21. Palatnik CB, Previato JO, Mendonça-Previato L et al. A new approach to phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasitol. Res. 76, 289-293 (1990).
22. Bouvier J, Etges R, Bordier C. Identification of the promastigote surface protease in seven species of Leishmania. Mol. Biochem. Parasitol. 24, 73-79 (1987).
23. Palatnik-de-Sousa CB, Gomes EM, Paraguai de Souza E et al. Leishmania donovani: titration of antibodies to the fucose mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 89, 390-393 (1995).
24. Borja Cabrera GP, da Silva VO, da Costa RT et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am. J. Trop. Med. 61, 296-301 (1999).
25. Palatnik-de-Sousa CB, Gomes EM, Paraguai de Souza E et al. The FML (fucose mannose ligand) of Leishmania donovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. Rev. Soc. Bras. Méd. Trop. 29, 153-163 (1996).
26. André R, Brumpt L, Dreyfus B et al. Leishmaniose cutanée, leishmaniose cutanée-ganglionnaire et kala-azar transfusionnel. Trop. Dis. Bull. 55, 379-381 (1958).
27. Cummins D, Amin S, Halil O et al. Visceral leishmaniasis after cardiac surgery. Arch. Dis. Child. 72, 235-236 (1995).
28. Cohen C, Corazza F, De Mol P et al. Leishmaniasis acquired in Belgium. Lancet 338, 128 (1991).
29. Mauny, I, Blanchot I, Degeilh B et al. Visceral leishmaniasis in an infant in Brittany: discussion of the modes of transmission out of endemic zones. Pediatrie. Bucur. 48, 237-239 (1993).
30. Luz KG, Gomes EM, da Silva VO et al. Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and polytransfused hemodialyzed patients. Am. J. Trop. Med. Hyg. 57, 168-171 (1997).
31. Otero ACS, da Silva VO, Luz KG et al. Occurrence of Leishmania donovani DNA in seroreactive Brazilian blood donors. Am. J. Trop. Med. Hyg. 62, 128-131 (2000).
32. Paraguai de Souza E, Borja Cabrera GP, Pereira TRD et al. Occurrence of Leishmania donovani DNA in bone marrow of FML-seroreactive Brazilian blood donors. Transfusion 39, 117S (1999).
33. Grogl M, Daugirda JM, Hoover DL et al. Survivability and infectivity of viscerotropic Leishmania tropica from Operation Desert Storm participants in human blood products maintained under blood bank conditions. Am. J. Trop. Med. Hyg. 49, 308-315 (1993).
34. Paraguai de Souza E, Esteves Pereira AP, Soares Machado FC et al. Visceral leishmaniasis: circulating Leishmania donovani parasites in blood of infected hamsters. Acta Trop. 80, 69-75 (2001).
35. Le Fichoux I, Quaranta JF, Aufevre JP et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J. Clin. Microbiol. 37, 1953-1957 (1999).
36. Riera C, Fisa R, López-Chejade P et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 18 (2008). (Epub ahead of print).
37. Giger U, Oakley DA, Owens SD et al. Leishmania donovani transmission by packed RBC transfusion to anemic dogs in the United States. Transfusion 42, 381-383 (2002).
38. Dodd RY. Transmission of parasites by blood transfusion. Vox Sang. 74, 161-163 (1998).
39. Commission Directive 2004/33/EC of 22 March 2004. Implementing Directive 2002/98/EC of the European Parliament and of Council as regards certain technical requirements for blood and blood components. Off. J. Eur. Union L 91, 25-39 (2004).
40. Palatnik-de-Sousa CB, Melo LMB, Borja-Cabrera GP et al. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. An. Acad. Bras.Cien. 76, 583-593 (2004).
41. Courtenay O, Quinnell RJ, Garcez LM et al. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J. Infect. Dis. 186, 1314-1320 (2002).
42. Machado Braga MD, Coelho ICB, Lima Pompeu M et al. Controle do calazar canino: comparação dos resultados de um programa de eliminação rápida de cães sororreagentes por ensaio imunoenzimático com outro de eliminação tardia de cães sororreagentes por teste de imunofluorescência indireta de eluato de papel filtro. Rev. Soc. Bras. Med. Trop. 31, 419-424 (1998).
43. Palatnik de Sousa CB. What is the potential use of serological tools in diagnosis of human kala-azar? (Analysis of specificity, sensitivity and predictive values). Rev. Bras. Med. Trop. 34, 55-57 (2002).
44. Ministério da Saúde, Sec. de Vigilância em Saúde. Dep de Vigilância epidemiológica. In: Manual de vigilância e controle da leishmaniose visceral. Série A. Normas e Manuais Técnicos. Ministério da Saúde (Ed.). Brasília, Basil 20-27 (2003).
45. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Review. Vaccine 26, 1709-1724 (2008).
46. Mohebali M, Khamesipour A, Mobedi I et al. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 22, 4097-4100 (2004).
47. Genaro O, Pinto JA, Da Costa CA et al. Phase III randomized double blind clinical trial on the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil. Mem. Inst. Oswaldo Cruz 91, 116 (1996).
48. Orenstein WA, Bernier RH, Dondero TJ et al. Field evaluation of vaccine efficacy. Bull. WHO 63, 1055-1068 (1985).
49. Goto H, Lindoso JAL. Immunity and immunosuppression in experimental visceral leishmaniasis. Braz. Med. J. Biol. Res. 37, 615-623 (2004).
50. da Silva VO, Borja-Cabrera GP, Correia Pontes NN et al. A Phase III trial of Efficacy of the FML- vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 19, 1068-1081 (2001).
51. Borja-Cabrera GP, Correia Pontes NN, da Silva VO et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil(São Gonçalo do Amarante). Vaccine 20, 3277-3284 (2002).
52. Palatnik-de-Sousa CB, Paraguai de Souza E, Gomes EM et al. Experimental murine Leishmania donovani infection: immunoprotection by the fucose mannose ligand (FML). Braz. J. Med. Biol. Res. 27, 547-551 (1994).
53. Palatnik-de-Sousa CB, Paraguai de Souza E, Gomes EM et al. The FML vaccine (fucose-manosse ligand) protects hamsters from experimental kala-azar. Ciência e Cultura. J. Braz. Assoc. Adv. Sci. 46, 290-296 (1994).
54. Santos WR, Paraguai de Souza E, Palatnik M et al. Vaccination with the FML antigen (fucose mannose ligand ) of Leishmania donovani in the Swiss albino model. Vaccine 17, 2554-2561 (1999).
55. Santos WR, de Lima VMF, Paraguai de Souza E et al. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21, 30-43 (2002).
56. Aguilar-Be I, Zardo RS, Paraguai de Souza E et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun. 73, 812-819 (2005).
57. Souza LOP, Palatnik-de-Sousa CB. Cross-protective efficacy of the prophylactic VR1012-NH36 Leishmania donovani DNA vaccine against cutaneous leishmaniasis by leishmanai amazonensis. Presented at: Vaccine Congress: 25 Years of Publication. Amsterdam, The Netherlands, 9-11 December 2007.
58. Oliveira-Freitas E, Casas CP, Borja-Cabrera GP et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24, 3909-3920 (2006).
59. Mendes CO, Kauffman C, Mello Machado A et al. Analysis of the hemolytic effect and in vivo toxicity of Quillaja brasiliensis saponins in the formulation of FMLvaccine against visceral leishmaniasis in mice. Mem. Inst. Oswaldo Cruz 95, 187 (2000).
60. Russell DG. Immunity to leishmaniasis: what properties delineate a protective antigen? Ann. Inst. Pasteur. Immunol. 138, 774-781 (1987).
61. Liew FY. Cell mediated immunity in experimental cutaneous leishmaniasis. Parasitol. Today 2, 264-270 (1986).
62. Rodrigues MM, Mendonça-Previato L, Charlab R et al. The cellular immune response to a purified antigen from Leishmania mexicana subsp. amazonensis enhances the size of the leishmanial lesion on susceptible mice. Infect. Immun. 55, 3142-3148 (1987).
63. Bradley DJ, Kirkley K. Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in the mice. Clin. Exp. Immunol. 30, 119-129 (1977).
64. Sharifi I, Fekri AR, Aflatonian MR et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351, 1540-1543 (1998).
65. Momeni AZ, Jalayer T, Emamjomeh M et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17, 466-472 (1999).
66. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice. Korean J. Parasitol. 45, 103-109 (2007).
67. Convit J, Ulrich M, Fernández CT et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 87, 444-448 (1993).
68. Gamboa-León R, Paraguai de Souza E, Borja Cabrera GP et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani. Vaccine 24, 4863-4873 (2006).
69. Barral-Netto M, Reed SG, Sadigursky M et al. Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes. Clin. Exp. Immunol. 67, 11-19 (1987).
70. Borja-Cabrera GP, Soares Machado, FC, Esteves AP et al. Vaccination against experimental canine kala-azar with the FML antigen of Leishmania donovani and Quil-A saponin. Mem. Inst. Oswaldo Cruz 93(Suppl. 2), 288 (1998).
71. Borja-Cabrera GP, Gonçalves da Costa S, Paraguai de Souza E et al. Protective effect of the FML+QuilA saponin vaccine against experimental canine kala-azar. Mem. Inst. Oswaldo Cruz 94(Suppl. 2), 204 (1999).
72. Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and type II of L. infantum. Vaccine 23, 3716-3725 (2005).
73. Ramiro MJ, Zárate JJ, Hanke T et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK. Vaccine 21, 2474-2484 (2003).
74. Atlet L, Francino O, Solano-Gallego L et al. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect. Immun. 70, 2763-2771 (2002).
75. Quinnell RJ, Kennedy LJ, Barnes A et al. Suscepibility to visceral leishmaniasis in domestic dog is associated with MHC class II polymorphism. Immunogenetics 55, 23-28 (2003).
76. Schetters TPM, Kleuskens J, Scholtes N et al. Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture. Paras. Immunol. 14, 295-305 (1992).
77. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infections. World Health Organization, Geneva, Switzerland, 1997.
78. Lemesre JL, Holzmuller P, Gonçalves RB et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25, 4223-4234 (2007).
79. Nogueira FS, Moreira MAB, Borja Cabrera GP et al. Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23, 4805-4810 (2005).
80. Keenan CM, Hendricks LD, Lightner L et al. Visceral leishmaniasis in the German shepherd dog. I. Infection, clinical disease, and clinical pathology. Vet. Pathol. 21, 74-79 (1984).
81. 2 antibody responses of dogs to Leishmania infantum and other parasites. Par. Immunol. 17, 451-458 (1995).
82. Nieto CG, Garcia Alonso M, Requena JM et al. Analysis of the humoral response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet. Immunol. Immunopathol. 67, 117-130 (1999).
83. Solano-Gallego L, Riera C, Roura X et al. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet. Parasitol. 96, 265-276 (2001).
84. 2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis.Vaccine 21, 2589-2597 (2003).
85. Santos FN, Borja-Cabrera GP, Miyashiro LM et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 25, 6176-6190 (2007).
86. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22, 2234-2243 (2004).
87. Vercammen F, Fernandez-Perez FJ, del Amo C et al. Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and western blot. Acta Trop. 84, 175-181 (2002).
88. 2 immunodetection patterns by western blot in asymptomatic, symptomatic and treated dogs. Acta Trop. 86, 83-91 (2003).
89. Reis AB, Teixeira-Carvalho A, Vale AM et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 112, 102-116 (2006).
90. Day MJ. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet. Parasitol. 147, 2-8 (2007).
91. Santana DM, Paraguai de Souza E, Borja-Cabrera GP et al. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis. Mol. Biochem. Parasitol.120, 315-319 (2002).
92. Fujiwara RT, Vale AM, Franca da Silva JC et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet. Res. 36, 827-838 (2005).
93. Andrade RA, Reis AB, Gontijo CM et al. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs. Vet. Immunol. Immunopathol. 116, 85-97 (2007).
94. Andrade PP, Menz I, Servio E et al. Serologic discrimination between vaccinated and infected dogs in visceral leishmaniasis. Presented at: Vaccine Congress: Celebrating 25 Years of Publication. Amsterdam, The Netherlands, 9-11 December 2007.
95. Bhatia A, Daifalla NS, Jen S et al. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol. Biochem. Parasitol. 102, 249-261 (1999).
96. Badaró R, Benson D, Eulálio MC et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J. Infect. Dis. 173, 758-761 (1996).
97. Borja Cabrera GP, Santos FN, Paraguai de Souza E et al. Phase I safety and immunogenicity trial of Leishmune® in dogs of Brazilian endemic areas. Presented at: Third World Congress on Leishmaniosis (Worldleish III). Palermo, Italy, 10-15 April 2005.
98. Parra LE, Borja-Cabrera GP, Santos FN et al. Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25, 2180-2186 (2007).
99. Rodrigues PN, Borja-Cabrera GP, Paraguai de Souza E et al. FML- vaccine formulation with increasing saponin concentrations in the Balb/c murine model. Rev. Inst. Med. Trop. SP. 44, 132 (2002).
100. Lemesre JL, Holzmuller P, Cavaleyra M et al. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23, 2825-2840 (2005).
101. Moreno J, Nieto J, Masina S et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.Vaccine 25, 5290-300 (2007).
102. Molano I, Alonso MG, Mirón C et al. Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 92, 1-13 (2003).
103. Gradoni L, Foglia Manzillo V, Pagano A et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected. Vaccine 23, 5245-5251 (2005).
104. UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases (TDR). Malaria transmission blocking vaccines: an ideal public good. UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases (TDR). TDR/RBM/MAL/VAC/2000.1 (consulted on 5 February, 2008)
105. Ingonga P, Mbati PA, Anjili CO et al. The effect of immune sera from hamsters immunized with sandfly gut and whole body extract antigens on fecundity and mortality of Phlebotomus duboscqi. Acta Trop. 60, 269-279 (1996).
106. Mbati PA, Anjili CO, Odongo S et al. Leishmania major infections in Phlebotomus duboscqi fed on murine models immunized with L. major subcellular antigens and sandfly gut antigens. Onderstepoort. J. Vet. Res. 67, 57-63 (2000).
107. Tonui WK, Mbati PA, Anjili CO et al. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis. East Afr. Med. J. 78, 84-89 (2001a).
108. Tonui WK, Mbati PA, Anjili CO et al. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunization using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in Balb/C mice. East Afr. Med. J. 78, 90-92 (2001b).
109. Saraiva EM, Mendes-Aguiar CO, Paraguai de Souza E et al. The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24, 2423-2431 (2006).
110. Travi BL, Tabares CJ, Cadena H et al. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am. J. Trop. Med. Hyg. 64, 119-224 (2001).
111. da Costa-Val AP, Cavalcanti RR, de Figueiredo Gontijo N et al. Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity. Vet. J. 174 636-643 (2007)
112. Titus RG, Bishop JV, Mejia JS. The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission. Parasite Immunol. 28, 131-41 (2006).
113. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol. 167, 5226-5230 (2001).
114. Santos WR, Bernardo RR, Peçanha LT et al. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine 15, 1024-1029 (1997).
115. Takechi M, Tanaka Y. Haemolytic time course differences between steroid and triterpenoid saponins. Planta Med. 61, 76-77 (1995).
116. Santos WR, Bernardo RR, Palatnik M et al. Selection of adjuvant for vaccination against experimental kala-azar. The FML antigen of Leishmania donovani in combination with saponin and sapogenin of Bredemeyera floribunda. Mem. Inst. Oswaldo Cruz 91, 167 (1996).
117. Palatnik-de-Sousa CB, Santos WR, Casas CP et al. Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.Vaccine 22, 2470-2479 (2004).
118. Kensil CR, Patel U, Lennick M et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146, 431-437 (1991).
119. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8, 934-943 (2003).
120. + T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis Vaccine 26, 2211-2224 (2008).
121. da Silva BP, Soares JBRC, Casas CP et al. Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for visceral leishmaniasis. Vaccine 23, 1061-1071 (2005).
122. Nico D, Santos FN, Borja-Cabrera GP et al. Assessment of the monoterpene, glycidic and triterpene-moieties' contributions to the adjuvant function of the CP05-saponin of Calliandra pulcherrima Benth. Vaccine 25, 940, 649-658 (2007).
123. 127 Nico D, Souza LOP, de Almeida LN et al. Kinins generated upon vaccination with the QS21 saponin-containing Leishmune® vaccine are partially responsible for induction of protective immunity against visceral leishmaniasis. Presented at: The Vaccine Congress. Celebrating 25 Years of Publication. Amsterdam, The Netherlands 9-11 December 2007.
124. Paraguai de Souza E, Bernardo RR, Palatnik M et al. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 19, 3104-3115 (2001).
125. Shi W, Schramm VL, Almo SC. Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-Å crystal structure. J. Biol. Chem. 274, 21114-21120 (1999).
126. Gopaul DN, Meyer SL, Degano M et al. Inosine-uridine nucleoside hydrolase from Crithidia fasciculata. Genetic characterization, crystallization, and identification of histidine 241 as a catalytic site residue. Biochemistry 35, 5963-5970 (1996).
127. Pellé R, Schramm VL, Parkin DW. Molecular cloning and expression of a purine-specific N-ribohydrolase from Trypanosoma brucei brucei. Sequence, expression and molecular analysis. J. Biol. Chem. 273, 2118-2126 (1998).
128. Mauricio IL, Yeo M, Baghaei M et al. Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GPI, NH1, NH2, PGD). Int. J. Parasitol. 36, 757-769 (2006).
129. Lukes J, Mauricio IL, Schönian G et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA 104, 9375-9380 (2007).
130. Al-Wabel MA, Tonui WK, Cui L et al. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania. Am. J. Trop. Med. Hyg. 77, 1060-1065 (2007).
131. Ghazanfari T, Hassan ZM, Ebtekar M et al. Garlic induces a shift in cytokine pattern in Leishmania major-infected Balb/c mice. Scand. J. Immunol. 52, 491-495 (2000).
132. Borja Cabrera GP, Santos FN, Miyashiro LM et al. Nucleoside hydrolase DNA vaccine against visceral leishmaniasis. Presented at: The Vaccine Congress. Celebrating 25 Years of Publication. Amsterdam, The Netherlands, 9-11 December 2007.
133. Universidade Federal do Rio de Janeiro, Clarisa B. Palatnik de Sousa and Radovan Borojevic, Brazilian patent INPI: (pipeline) PI1100173-9.
134. The European Molecular Biology Laboratory, Genbank™ and DDJB data bases, access number: AY007193.
135. World Health Organization-TDR. The TDR fifteenth programm report. Research progress 1999-2000. New and improved tools. 2003 www.who.int/tdr/ research/progress 9900/tools/vdr.htm (Accessed 5 February 2008).
136. Bernardo RR, Palatnik de Sousa CB, Parente JP. N-linked oligosaccharide structures of the FML antigen of Leishmania (L.) donovani. Mem. Inst. Oswaldo Cruz MEMIOC. 93, 179 (1998) www.scielo.br/pdf/mioc/v93s2/bc.pdf
137. US Food and Drug Administration www.fda.gov/bbs/topics/ANSWERS/ ANS00360.html
138. Dumonteil E, McMahon-Pratt D, Price VL. Report of the fourth TDR/IDRI meeting on second generation Vaccines against leishmaniaisis. UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR). TDR/WHO (Ed.) Geneva SW,10, (2001) www.who.int/leishmaniasis/ resources/documents/en/TDR_PRD_LEISH_VAC_01.1.pdf.